As of June 30, 2023, unrestricted cash and cash equivalents were $38.8 million, compared to $55.4 million as of March 31, 2023. Freeline expects its current level of cash and cash equivalents will enable the company to fund its planned operations into the second quarter of 2024.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FRLN:
- Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
- Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
- Freeline to hold a virtual event
- Freeline to Participate in Upcoming Investor Conferences
- Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease